About
About us
Team
Scientific Advisors
Sevuparin
About Sevuparin
Action of sevuparin in septic shock
Further reading
Systemic Inflammation
About Systemic Inflammation
Sepsis and sceptic shock
Sevuparin Clinical Program
Investors
IPO 2021
Share
News
Financial Reports
Presentations
Calendar
Corporate Governance
Analyst Coverage
News
Contact
EN
SV
All Press Releases
ALL PRESS RELEASES 2021
Jun 11, 2021
Modus Therapeutics and Imperial College London Sign Clinical Collaboration Targeting Severe Malaria
>
May 6, 2021
Modus Therapeutics publishes interim report for Q1
>
Apr 20, 2021
Notice to Annual General Meeting in Modus Therapeutics Holding AB
>
Mar 15, 2021
Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
>
Mar 12, 2021
Modus Therapeutics – Claes Lindblad Joins as Chief Financial Officer
>
Mar 10, 2021
Modus Therapeutics Announces New Strategy for the Clinical Development of Sevuparin as a Potential Treatment for Sepsis/Septic shock
>
